Business context and reporting period
Filing identity mismatch: The request identifies Gyre Therapeutics, Inc., but the supplied Form 10-Q is for Catalyst Biosciences, Inc. (Nasdaq: CBIO). The summary below reflects the supplied filing, for the quarter ended September 30, 2019, filed November 7, 2019.
Catalyst was a clinical-stage biopharmaceutical company developing engineered coagulation factors for hemophilia and other rare bleeding disorders. It had no products approved for sale and no product-sales revenue.
Financial results and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0.006 million |
| Research and development expense | $9.9 million | $5.6 million | $33.1 million | $13.2 million |
| General and administrative expense | $3.3 million | $2.8 million | $10.2 million | $8.9 million |
| Net loss | $12.7 million | $7.7 million | $41.6 million | $19.2 million |
| Basic and diluted loss per share | $1.06 | $0.64 | $3.47 | $1.75 |
| Operating cash used | Not presented quarterly | Not presented quarterly | $35.5 million | $19.5 million |
At September 30, 2019, cash and cash equivalents were $23.0 million and short-term investments were $61.9 million, totaling $85.0 million. Current assets were $89.1 million against current liabilities of $9.1 million. Total liabilities were $10.5 million, including $1.9 million of operating lease liabilities; the filing reports no borrowings. Stockholders’ equity was $81.3 million. Operating margins are not meaningful given the absence of revenue.
Nine-month investing cash flow was positive $27.0 million, primarily reflecting investment maturities net of purchases; financing cash flow was positive $0.3 million. Cash, cash equivalents and restricted cash declined $8.2 million over the period. The accumulated deficit was $244.9 million.
Material changes versus comparable periods
- Q3 net loss increased 65% year over year; nine-month net loss increased 116%.
- R&D expense rose 78% for the quarter and 150% for the nine-month period, driven mainly by clinical and manufacturing work on MarzAA and DalcA, preclinical research and personnel costs.
- G&A expense increased 18% for the quarter and 15% for nine months. Interest and other income declined 25% and 41%, respectively; the 2018 nine-month comparison included a $1.5 million milestone receipt.
- Cash and short-term investments fell from $120.1 million at December 31, 2018 to $85.0 million at September 30, 2019. The 2018 period included $106.8 million of net public-offering proceeds; there was no comparable offering in 2019.
Outlook, developments and risks
- Management expected existing cash, cash equivalents and short-term investments to fund requirements for at least 12 months from the filing date, while cautioning that assumptions could prove incorrect. It anticipated continued losses and increasing R&D spending as MarzAA and DalcA development advanced.
- MarzAA Phase 2 results reported in July showed mean annualized bleeding rate declining from 19.8 before treatment to 1.6 at final dose levels; management planned to initiate a Phase 3 study in 2020 and expected Phase 1 SQ data in 2020.
- DalcA Phase 2b enrollment was ongoing; management anticipated final data in the first half of 2020. Two subjects had exceeded the trial’s stated Factor IX activity endpoint, with no antibodies detected in those two subjects; injection-site reactions were also reported.
- The company had $5.4 million remaining in firm manufacturing work orders with AGC Biologics, against $12.4 million of total commitments. A Catalent clinical-supply agreement was signed after quarter-end; there were no firm work orders at September 30.
- Pfizer milestone payments could total up to $17.5 million, and ISU Abxis milestones up to $19.5 million; future product royalties may also apply. No Pfizer payments were made in the first nine months of 2019.
- Additional funding might be needed and could be unavailable or dilutive. Management said it might delay or reduce programs if financing prospects weakened. Two stockholders had sought board representation; the filing added risks from potential activist campaigns, proxy contests, related costs and business distraction.
- The company had no material legal proceedings and reported no material change to previously disclosed risk factors apart from the added activist-stockholder risk.
Most important facts to verify
- Confirm the intended issuer: this source is Catalyst Biosciences, not Gyre Therapeutics.
- Assess whether the stated 12-month cash runway remains adequate in light of operating cash burn, planned clinical/manufacturing spending and subsequent developments.
- Track MarzAA Phase 3 timing and DalcA Phase 2b results, including safety, immunogenicity and regulatory implications.
- Verify future financing needs, potential dilution and the status of AGC commitments, collaboration milestones and royalties.
- Monitor the activist-stockholder situation and any resulting governance, litigation or expense effects.